WUXI BIOLOGICS TO PARTICIAPTE AT 41st ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
San Francisco, California, USA, January 6, 2023 – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global CRDMO service company, announced today that it will participate in the 41st Annual J.P. Morgan Healthcare Conference at the Westin St. Francis in San Francisco, California. Chris Chen Ph.D., CEO of WuXi Biologics, will present the keynote of “Global Premier CRDMO: Enabling Global Partners and Delivering Sustainable High Growth” on January 11 at 9:45am-10:25am PST.
A live audio steam and an archived presentation will be available on the Investor Events section of the WuXi Biologics website: https://www.wuxibiologics.com/investor-events#presentations_webcasts
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 10,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com.